الصفحة الرئيسية>>Signaling Pathways>> Others>> Inhibitory Antibodies>>Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)

رقم الكتالوجGC72330

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) هو مثبط مستمد من الجرذان IgG1, κ type antibody inhibitor، يستهدف الماوس CD106/VCAM-1.

Products are for research use only. Not for human use. We do not sell to patients.

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) التركيب الكيميائي

الحجم السعر المخزون الكميّة
1 mg
180٫00
متوفر
5 mg
549٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD106/VCAM-1.

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].

References:
[1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103.

مراجعات

Review for Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.